For early-stage (I and II) disease, the sensitivity of CTC detection was 67.19%, which is higher than that of most serum tumor markers such as CEA, CA 19-9, and CYFRA 21-1 (27, 28). This evidence concerns the gene CEACAM5 and neoplasm.